20 results about "Phenylacetones" patented technology

Methods and devices are provided for capturing and using quantitative and qualitative results from point-of-collection devices for different diagnostic assays on a mobile device application. In one nonlimiting embodiment, these methods and devices are used in the diagnosis and / or monitoring of phenylketonuria (PKU).

This utility model discloses a mother liquor recovery device for crude p-methylphenylacetone, comprising: a support plate and auxiliary components. The support plate has second mounting grooves on both its front and rear sides on its lower surface. A hydraulic pump is fixedly connected to the inner surface of the second mounting groove. A hydraulic rod is fixedly connected to the output end of the hydraulic pump. A lower pressure plate is fixedly connected to the lower surface of the hydraulic rod. An auxiliary rod is fixedly connected to the upper surface of the lower pressure plate. A limit plate is fixedly connected to the outer surface of the auxiliary rod, and a spring abuts against the upper surface of the limit plate. Through the sliding guide structure of the auxiliary rod and the fixed block, the horizontal offset of the lower pressure plate during lifting is controlled to a minimal range, ensuring the uniformity and accuracy of the mother liquor recovery pressure. The rigid support characteristics of the spring evenly distribute the pressure transmitted by the hydraulic rod to the support plate, reducing fatigue wear of key components and extending the service life of core components such as the hydraulic pump and hydraulic rod.

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein.These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

This invention discloses a recombinant *E. coli* strain for producing phenyllactic acid, a lactate dehydrogenase mutant, a whole-cell catalytic method for preparing phenyllactic acid, and the application of the aforementioned recombinant *E. coli* strain or lactate dehydrogenase mutant in the catalytic preparation of phenylpyruvic acid from phenyllactic acid. This invention significantly improves catalytic efficiency by modifying the 52nd amino acid of lactate dehydrogenase through site-directed mutagenesis. After mutating glutamine (Q) to valine (V) at position 52 of the *Lactobacillus mucosa* lactate dehydrogenase, the catalytic efficiency is significantly improved even at low cell density (OD). 600 =15) and substrate 15 g / L conditions, almost complete conversion was achieved; and combined with high-density catalysis and surface display optimization, the yield of phenyl lactic acid was increased while the downstream separation and purification costs were significantly reduced, greatly enhancing the potential for industrial production.

This invention belongs to the field of pharmaceutical synthesis, specifically relating to a method for preparing etorizine hydrochloride and its intermediates. Specifically, it involves reacting propionyl chloride and ethylbenzene at -80 to -50°C to obtain p-ethylphenylacetone, which is then reacted with piperidine and paraformaldehyde to form a salt, yielding etorizine hydrochloride. The method for preparing p-ethylphenylacetone provided by this invention can obtain a product with a low content of compound II. Using this as a raw material to prepare etorizine hydrochloride simplifies post-processing, improves yield, and ensures that the content of compound III meets pharmacopoeia standards, making it suitable for industrial production.

This invention discloses a method for preparing a self-healing hydrogel with both sensing and antibacterial properties. The invention uses a hydrogel prepared from acrylamide (AM) and 2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide (SBMA) and cellulose nanofibers (CNF) as a matrix, silver-coated polydopamine nanoparticles (Ag@PDA NPs) as antibacterial and conductive agents, and 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone (I2959) and polyethylene glycol diacrylate (PEGDA) as photoinitiators and crosslinking agents. A multifunctional hydrogel with multiple dynamic reversible bonds is prepared by ultraviolet light-initiated self-polymerization. By constructing various dynamic reversible interactions, including covalent and non-covalent bonds and interionic interactions, a self-healing Ag@PDA NPs / AM / SBMA / CNF hydrogel was obtained. Ag and DA were introduced to prepare Ag@PDA with antibacterial, adhesive, and electronic conductivity properties, while zwitterionic SBMA was introduced to provide ionic conductivity. The synergistic effect of these two compounds endows the hydrogel with electrical conductivity. The hydrogel dressing prepared by this method can achieve rapid sterilization while possessing excellent biocompatibility, high adhesion, high conductivity sensing ability, and environmental adaptability.

The application belongs to the technical field of gene detection and molecular diagnosis, and particularly relates to a kit for detecting a pathogenic gene of phenylketonuria and application thereof. The kit comprises a primer pair for amplifying specific exons and splicing regions of a phenylalanine hydroxylase gene, and specific probes for detecting hot spot mutations and deletion / repetition variations of the gene. The application can detect genetic variations related to phenylketonuria in one time, quickly and accurately by combining optimized multiplex polymerase chain reaction with high-throughput sequencing or gene chip technology, and covers various known hot spot mutations and copy number variations including c.1222C>T, c.1068-11G>A, c.728G>A and c.1162G>A. The kit has high detection sensitivity and strong specificity, and is suitable for positive recall diagnosis of neonatal phenylketonuria screening, genetic diagnosis of suspected patients, carrier screening and prenatal diagnosis, and provides an efficient tool for precise prevention and control of phenylketonuria.

This invention relates to the pharmaceutical field, specifically disclosing a pharmaceutical composition and its application. The composition comprises sibifluin, uridine, and adenosine, wherein the mass ratio of sibifluin:uridine:adenosine is 6.0-11.5:0.8-1.4:1.0. This pharmaceutical composition exhibits good safety and anti-inflammatory effects, demonstrates good efficacy in the treatment of phenylketonuria, and also shows good preventative and / or therapeutic effects against ovarian insufficiency.

This invention belongs to the field of quality control technology, specifically relating to a quality control method for a compound traditional Chinese medicine preparation containing rhubarb. The quality control method of this invention uses thin-layer chromatography (TLC) to identify rhubarb, Viola yedoensis, Kochia scoparia, Cnidium monnieri, Coptis chinensis, or Dictamnus dasycarpus in a rhubarb antipruritic lotion. The method uses a developing solvent with a volume ratio of toluene, acetone, ethyl acetate, and formic acid of 8-10:1-3:1-2:0.1-2 to separate and extract the components to be analyzed from numerous effective drug components. While ensuring identification accuracy, this method allows for the identification of 4-6 traditional Chinese medicine components using a single TLC plate, exhibiting high stability and repeatability. This invention offers the technical advantages of requiring less sampling, simplifying quality testing, and greatly improving detection efficiency.

This invention discloses a photothermal dual-curing anti-fogging window film and its preparation method, relating to the field of film technology. In preparing the photothermal dual-curing anti-fogging window film, the invention involves: chlorinating an anti-UV monomer with thionyl chloride to obtain a pre-modified anti-UV monomer, which is then reacted with 4-penten-1-ol to obtain a modified UV-absorbing monomer; reacting a Schiff base intermediate with 9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide to obtain a flame retardant; reacting the flame retardant with pure bromine via a Hoffmann degradation reaction to obtain a modified flame retardant; and mixing acrylic resin, the modified flame retardant, 2-hydroxy-2-methylphenylacetone, dioctyl phthalate, a leveling agent, ethyl acetate, and toluene, followed by coating and curing to obtain the photothermal dual-curing anti-fogging window film. The photothermal dual-curing anti-fogging window film prepared by this invention exhibits excellent anti-fogging, flame-retardant, and UV-resistant properties.

In one aspect, the present disclosure provides a method of synthesis for methylone HCl, with 3,4-methylenedioxypropiophenone (MDP) as the starting material. In another aspect, the present disclosure provides stereoisomers of methylone. In another aspect, the present disclosure provides phenethylamines or cathinones covalently bound to a chemical moiety in a prodrug form. The presently described prodrug form allows slow / sustained / controlled delivery of the parent phenethylamines or cathinones into the blood system in a manner that would increase the duration of therapeutic efficacy.

This invention relates to a phenylpyruvate decarboxylase mutant for the synthesis of phenylethanol and its applications, belonging to the fields of enzyme engineering and genetic engineering. To address the technical problems of low catalytic efficiency, poor substrate affinity, and insufficient stability of existing phenylpyruvate decarboxylases, which lead to low biosynthetic efficiency and limited yield of phenylethanol, making it difficult to meet the needs of industrial production, this invention provides a phenylpyruvate decarboxylase mutant for the synthesis of phenylethanol. This mutant offers a new and highly efficient synthetic element for the biosynthesis of phenylethanol, with broad application prospects and market potential in the field of higher alcohol synthesis.

This invention relates to polymorphs of metoprolol and its salts. Crystal forms and combinations thereof of the free base of metoprolol selected from polymorphs A, B, C, D, E, F, and G are disclosed, as well as crystalline polymorphs of salts of metoprolol. Pharmaceutical compositions containing one or more of these polymorphs and methods for preparing such polymorphs are also disclosed. Metoprolol can be used to treat a variety of diseases associated with low intracellular BH4 levels, such as phenylketonuria.

The present disclosure relates to an optimized PAH gene and an expression cassette and use thereof. Specifically, a polynucleotide molecule encoding PAH protein is disclosed. By means of using the polynucleotide molecule, expression cassette, expression vector, virion, and / or pharmaceutical composition provided herein, human PAH can be effectively, persistently, and stably expressed in the liver at a relatively low dose, thus steadily keeping the blood phenylalanine concentration in a subject at a relatively low level for a long period. Therefore, the present disclosure can be used for the treatment of phenylketonuria.

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof, as well as methods for treating hyperphenylalaninemia (HPA), in particular phenylketonuria (PKU), using the compounds.

This invention relates to the field of cosmetic raw material processing technology, and discloses a preparation process for active nano-encapsulated materials for cosmetics. The preparation process is as follows: Cosmetic active ingredients are added to an alkenylated modified chitosan solution and ultrasonically treated for 1-3 minutes. Then, thiolated silk fibroin is added and mixed evenly. Next, a photoinitiator, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone, is added to the system. The mixture is irradiated under 365 nm ultraviolet light at room temperature for 10-20 minutes to obtain a dispersion of nano-hydrogel encapsulated materials containing the active ingredients. After ultrafiltration purification, 5% (w / w) of trehalose is added, stirred to dissolve, and freeze-dried to obtain active nano-encapsulated materials for cosmetics. The active nano-encapsulated materials for cosmetics prepared by this invention exhibit good stability, sustained-release and controlled-release properties, and antioxidant properties.

The present invention relates to infant formula or follow-on formula suitable for children up to 2 years of age, and their use in the dietary management of phenylketonuria and tyrosinemia. In particular, the present invention relates to infant formula or follow-on formula comprising casein glycomacropeptide and free amino acids, and their use in the dietary management of phenylketonuria and tyrosinemia and their symptoms. The present invention relates to a mixture of free amino acids for use in the manufacture of infant formula or follow-on formula.

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A 19 transport.